Randomized, Single-dose, Parallel-arm, Open-label Phase I Trial to Compare the Pharmacokinetics, Safety and Tolerability of BI 695501 Administered Subcutaneously Via Prefilled Syringe or Autoinjector
Phase of Trial: Phase I
Latest Information Update: 17 Mar 2017
At a glance
- Drugs Adalimumab (Primary)
- Indications Crohn's disease; Plaque psoriasis; Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 14 Mar 2017 Status changed from active, no longer recruiting to completed.
- 14 Feb 2017 Status changed from recruiting to active, no longer recruiting.
- 03 Oct 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Feb 2017.